dc.contributor.author | Latifoltojar, A | |
dc.contributor.author | Boyd, K | |
dc.contributor.author | Riddell, A | |
dc.contributor.author | Kaiser, M | |
dc.contributor.author | Messiou, C | |
dc.date.accessioned | 2020-11-04T12:27:22Z | |
dc.date.issued | 2021-01-01 | |
dc.identifier.citation | Magnetic resonance imaging, 2021, 75 pp. 60 - 64 | |
dc.identifier.issn | 0730-725X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4216 | |
dc.identifier.eissn | 1873-5894 | |
dc.identifier.doi | 10.1016/j.mri.2020.10.005 | |
dc.description.abstract | Diagnosis of patients suspected of multiple myeloma requires a combination of serological and biochemical tests, bone marrow aspirate (BMA) and/or bone marrow trephine (BMT) biopsies as well as complementary information provided by whole-body cross-sectional imaging studies. However, given the heterogeneous nature of multiple myeloma, discrepancies can arise between disease burden on trephine and extent of disease within the marrow on whole-body magnetic resonance imaging (WB-MRI). Here, for the first time, we report on a series of symptomatic multiple myeloma patients for whom there was substantial discordance between disease burden on trephine and WB-MRI. | |
dc.format | Print-Electronic | |
dc.format.extent | 60 - 64 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE INC | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Characterising spatial heterogeneity of multiple myeloma in high resolution by whole body magnetic resonance imaging: Towards macro-phenotype driven patient management. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-10-14 | |
rioxxterms.versionofrecord | 10.1016/j.mri.2020.10.005 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2021-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Magnetic resonance imaging | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Myeloma Group | |
pubs.publication-status | Published | |
pubs.volume | 75 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Myeloma Group | |
dc.contributor.icrauthor | Kaiser, Martin | |